Lung Cancer Clinical Trial
Official title:
A Pilot Clinical Trial Looking at the Effect on Lung Cancer Diagnosis of Giving a CXR to Smokers Aged Over 60 With Chest Symptoms
Verified date | April 2011 |
Source | National Cancer Institute (NCI) |
Contact | n/a |
Is FDA regulated | No |
Health authority | Unspecified |
Study type | Interventional |
RATIONALE: Diagnostic procedures, such as an urgent chest x-ray, may help in planning cancer
treatment. It is not yet known whether standard medical care is more effective than an
urgent x-ray in diagnosing lung cancer in smokers with chest symptoms who are older than 60
years.
PURPOSE: This randomized clinical trial is studying standard medical care to see how well it
works compared with an urgent chest x-ray in diagnosing lung cancer in smokers with chest
symptoms who are older than 60 years.
Status | Not yet recruiting |
Enrollment | 386 |
Est. completion date | |
Est. primary completion date | June 2013 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 60 Years and older |
Eligibility |
DISEASE CHARACTERISTICS: - Patients over 60 seeing a participating General Practitioner - Currently smokes 10 or more pack years, meeting at least one of the following criteria: - New or altered cough of any duration reported to primary care - Increased breathlessness or wheezing (with or without purulent sputum) - Do not qualify for an urgent referral for a chest x-ray under the National Institute for Health and Clinical Excellence (NICE) guidelines (i.e., hemoptysis or unexplained or persistent [lasting > 3 weeks] signs or symptoms), including having any of the following: - Cough - Chest/shoulder pain - Dyspnea - Weight loss - Chest signs - Hoarseness - Finger clubbing - Features suggestive of metastasis from a lung cancer (e.g., in the brain, bone, liver, or skin) - Cervical/supraclavicular lymphadenopathy PATIENT CHARACTERISTICS: - Not specified PRIOR CONCURRENT THERAPY: - No chest x-ray within in past 3 months - No need for a chest x-ray within the next 3 weeks for reasons other than those listed under Disease Characteristics |
Allocation: Randomized, Masking: Open Label, Primary Purpose: Diagnostic
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Wales Cancer Trials Unit |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Prevalence of extra-NICE symptoms in patients consulting in UK general practice | No | ||
Primary | Proportion of patients who agree to participate in the trial | No | ||
Primary | Proportion of patients who are diagnosed with lung cancer and the best sources of routine data for capturing lung cancers | No | ||
Secondary | Best way to train general practitioners to identify and recruit eligible patients into the trial | No | ||
Secondary | Most effective method of presenting the trial (and randomization) to patients | No | ||
Secondary | Barriers to recruitment and how to overcome those barriers | No | ||
Secondary | Best tools to use to measure anxiety/depression that may be caused by unnecessary chest-x-rays or no chest x-rays | No | ||
Secondary | Best measures of resource use to facilitate health economic analysis of the cost-effectiveness of 'extra-NICE' | No | ||
Secondary | Stage at diagnosis, performance status, and the proportion of patients receiving radical treatments in those diagnosed with lung cancer | No | ||
Secondary | False-positive and false-negative rates for chest x-rays | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03918538 -
A Series of Study in Testing Efficacy of Pulmonary Rehabilitation Interventions in Lung Cancer Survivors
|
N/A | |
Recruiting |
NCT05078918 -
Comprehensive Care Program for Their Return to Normal Life Among Lung Cancer Survivors
|
N/A | |
Active, not recruiting |
NCT04548830 -
Safety of Lung Cryobiopsy in People With Cancer
|
Phase 2 | |
Completed |
NCT04633850 -
Implementation of Adjuvants in Intercostal Nerve Blockades for Thoracoscopic Surgery in Pulmonary Cancer Patients
|
||
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT05583916 -
Same Day Discharge for Video-Assisted Thoracoscopic Surgery (VATS) Lung Surgery
|
N/A | |
Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
Not yet recruiting |
NCT06376253 -
A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers
|
Phase 1 | |
Recruiting |
NCT05898594 -
Lung Cancer Screening in High-risk Black Women
|
N/A | |
Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03575793 -
A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
Terminated |
NCT01624090 -
Mithramycin for Lung, Esophagus, and Other Chest Cancers
|
Phase 2 | |
Terminated |
NCT03275688 -
NanoSpectrometer Biomarker Discovery and Confirmation Study
|
||
Not yet recruiting |
NCT04931420 -
Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels
|
Phase 2 | |
Recruiting |
NCT06052449 -
Assessing Social Determinants of Health to Increase Cancer Screening
|
N/A | |
Recruiting |
NCT06010862 -
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
|
Phase 1 | |
Not yet recruiting |
NCT06017271 -
Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
|
||
Recruiting |
NCT05787522 -
Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk
|